Covidien (COV) issues FY13 guidance, saying it expects revenues to increase 3% to 6% over the prior year, and its plans to spin off its pharmaceuticals business into a stand-alone public company are on track. Pharmaceutical sales are projected to be up 1% to 4%, and 4% to 7% in its medical devices segment. Operating margins should be in the 22% to 23% range with an effective tax rate of 18% to 19%.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.